Longstanding claims that one of the reasons for high drug prices in the US is the actions of pharmacy benefit management ... investigated by the Federal Trade Commission (FTC).

Agency commissioners voted unanimously on Tuesday to publish the report, which makes a similar attack on the drug middlemen as the agency’s first report, but draws on more data.

The Federal Trade Commission has released its second report digging into how the business practices of pharmacy benefit managers ... The Pharmaceutical Care Management Association, the largest ...

In the days leading up to President Trump’s inauguration, the Biden FTC rushed to initiate major lawsuits and to tie a bow on ...

Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.

The Federal Trade Commission published a second interim staff report on the prescription drug middleman industry, which focuses on pharmacy benefit managers’ influence over specialty generic ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.